{"id":15814,"date":"2023-07-27T23:21:00","date_gmt":"2023-07-27T15:21:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15814"},"modified":"2024-11-29T23:42:06","modified_gmt":"2024-11-29T15:42:06","slug":"abbvie-and-calibr-announce-strategic-collaboration-to-advance-preclinical-research","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15814","title":{"rendered":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research"},"content":{"rendered":"\n

AbbVie (NYSE: ABBV<\/a>) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug candidates. Under the new agreement, Calibr will conduct preclinical research for a period of five years, receiving research option payments from AbbVie, who will have the first-exclusive option to develop and commercialize any candidates resulting from this work.<\/p>\n\n\n\n

Financial Terms and Potential Milestones<\/strong>
If AbbVie exercises its option to a specific program, Calibr will be eligible to receive additional payments, including option exercise fees, success-based development, and commercial milestone payments, as well as tiered royalties on any future sales. The specific financial details of the deal were not disclosed.<\/p>\n\n\n\n

Leveraging Calibr’s Cell Therapy Expertise<\/strong>
According to a notice from Scripps, the collaboration will particularly leverage Calibr’s capabilities in the cell therapy field. Calibr’s chimeric antigen receptor (CAR) T cell platform is known for its ability to design CAR-Ts with enhanced safety, versatility, and efficacy. The platform utilizes a proprietary modular “switchable” CAR-T cell technology that employs antibody-based switch molecules to control activation and antigen specificity. This innovative technology also supports the development of ‘universal’ CAR-Ts, potentially revolutionizing the field of cell therapy.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[234,2485,853],"class_list":["post-15814","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abbvie","tag-calibr","tag-nyse-abbv"],"yoast_head":"\nAbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug candidates. Under the new agreement, Calibr will conduct preclinical research for a period of five years, receiving research option payments from AbbVie, who will have the first-exclusive option to develop and commercialize any candidates resulting from this work.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15814\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15814\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-27T15:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T15:42:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research\",\"datePublished\":\"2023-07-27T15:21:00+00:00\",\"dateModified\":\"2024-11-29T15:42:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"Calibr\",\"NYSE: ABBV\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15814#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15814\",\"name\":\"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-27T15:21:00+00:00\",\"dateModified\":\"2024-11-29T15:42:06+00:00\",\"description\":\"AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug candidates. Under the new agreement, Calibr will conduct preclinical research for a period of five years, receiving research option payments from AbbVie, who will have the first-exclusive option to develop and commercialize any candidates resulting from this work.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15814\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15814#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research - Insight, China's Pharmaceutical Industry","description":"AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug candidates. Under the new agreement, Calibr will conduct preclinical research for a period of five years, receiving research option payments from AbbVie, who will have the first-exclusive option to develop and commercialize any candidates resulting from this work.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15814","og_locale":"en_US","og_type":"article","og_title":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15814","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-27T15:21:00+00:00","article_modified_time":"2024-11-29T15:42:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15814#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15814"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research","datePublished":"2023-07-27T15:21:00+00:00","dateModified":"2024-11-29T15:42:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15814"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","Calibr","NYSE: ABBV"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15814#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15814","url":"https:\/\/flcube.com\/?p=15814","name":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-27T15:21:00+00:00","dateModified":"2024-11-29T15:42:06+00:00","description":"AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research institute Scripps Research, have unveiled a strategic collaboration aimed at advancing preclinical research. This partnership builds on previous work with Scripps that has already led to the development of several preclinical and early clinical drug candidates. Under the new agreement, Calibr will conduct preclinical research for a period of five years, receiving research option payments from AbbVie, who will have the first-exclusive option to develop and commercialize any candidates resulting from this work.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15814#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15814"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15814#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15814"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15814\/revisions"}],"predecessor-version":[{"id":15816,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15814\/revisions\/15816"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}